Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus TRIOSTAT.
LEVOTHYROXINE SODIUM vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone